Aquestive Therapeutics, Inc. (NASDAQ:AQST) filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026.
Key Highlights
- Shares outstanding: 125,687,705 shares of common stock, par value $0.001 per share, were outstanding as of October 30, 2026, according to the filing.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, as disclosed on the cover page.
- Debt refinancing: The 13.5% Senior Secured Notes were redeemed on May 12, 2026, the same date identified as the effective date of a new Credit Agreement with Oaktree Capital Management, L.P.
- Term Loan Facility: The filing identifies a senior secured term loan facility of up to $150,000, structured across four tranches: Tranche A ($55,000), Tranche B ($20,000), Tranche C ($25,000), and Tranche D ($50,000).
- Prior capital raise: The filing references a 2025 Underwritten Public Offering that raised gross proceeds of $85,000, according to the glossary of terms.
- Warrant activity: The filing identifies RTW Warrants to purchase 375,000 shares at an exercise price of $4.00 per share, and New Warrants to purchase 2,750,000 shares of common stock.
- Pipeline platform: The filing references AdrenaVerse, described as an epinephrine prodrug platform currently comprised of Anaphylm (dibutepinephrine) sublingual film and AQST-108.
Aquestive Therapeutics Files Third-Quarter 2026 Report Covering Debt Transition and Capital Structure
Aquestive Therapeutics, Inc., a Delaware-incorporated specialty pharmaceutical company headquartered in Warren, New Jersey, filed its quarterly report covering the three and nine months ended September 30, 2026. The company's common stock trades on the Nasdaq Global Market under the symbol AQST. As of October 30, 2026, the company reported 125,687,705 shares of common stock outstanding, with a par value of $0.001 per share.
According to the filing, a significant development during the period was the redemption of the company's 13.5% Senior Secured Notes on May 12, 2026, which the filing identifies as the effective date of a new Credit Agreement with funds managed by Oaktree Capital Management, L.P. The new facility is described as a senior secured term loan of up to $150,000 in aggregate principal, divided into four tranches. Tranche A represents an initial funded amount of $55,000. Tranche B carries a $20,000 principal amount and is associated with a minimum net sales covenant if drawn. Tranche C is $25,000 and Tranche D is $50,000, according to the glossary included in the filing.
The filing also references warrant instruments tied to recent financing arrangements. RTW Warrants, issued in connection with a Purchase and Sale Agreement with RTW Investments, LP, provide the right to purchase 375,000 shares of common stock at an exercise price of $4.00 per share. Separately, New Warrants cover 2,750,000 shares of common stock, and a Tranche A Warrant covers up to an aggregate of 230,271 shares, according to the filing's glossary. On the product side, the filing identifies Aquestive's AdrenaVerse platform as an epinephrine prodrug platform currently comprised of Anaphylm (dibutepinephrine) sublingual film and a compound designated AQST-108. The filing also references Libervant (diazepam) buccal film, indicated for acute repetitive seizures, among the company's products.
What Was Disclosed
Aquestive Therapeutics filed a quarterly report for the period ended September 30, 2026, disclosing 125,687,705 shares outstanding, a new $150,000 term loan facility with Oaktree Capital Management, L.P., the redemption of its 13.5% Senior Secured Notes, and details on its warrant instruments and product pipeline.





Please wait processing your request...